How does the GH-IGF-1 axis work?

Growth hormone (GH) is secreted in pulsatile bursts from somatotroph cells in the anterior pituitary in response to hypothalamic GHRH and ghrelin receptor agonism. In the liver, GH binds the GH receptor (GHR), a transmembrane receptor that activates the JAK2-STAT5 signalling pathway upon GH binding. STAT5b, the primary hepatic STAT isoform, translocates to the nucleus and drives transcription of IGF-1 (insulin-like growth factor 1). Secreted hepatic IGF-1 enters the bloodstream, where the majority is bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, forming ternary complexes with the acid-labile subunit (ALS). These ternary complexes extend IGF-1 half-life from approximately 10 minutes for free IGF-1 to 12 to 15 hours for the bound fraction, creating a stable circulating reservoir. Free IGF-1 (the biologically active fraction) acts on IGF-1 receptors in muscle, bone, and other peripheral tissues to mediate the anabolic and growth-promoting effects of GH. Locally produced IGF-1 in muscle, bone, and cartilage (autocrine/paracrine IGF-1, driven by local GHR activation) contributes independently of circulating hepatic IGF-1.

What is the difference between PI3K-Akt and MAPK-ERK downstream signalling?

IGF-1 receptor activation triggers two principal downstream signalling cascades with distinct biological outputs. The PI3K-Akt pathway is the primary anabolic and survival pathway: IGF-1R activates PI3K (phosphoinositide 3-kinase) via IRS-1 (insulin receptor substrate 1), which phosphorylates PIP2 to PIP3. PIP3 recruits Akt (also known as protein kinase B) and PDK1 to the membrane, where Akt is phosphorylated and activated. Activated Akt has multiple downstream targets: it activates mTOR complex 1 (mTORC1), which drives protein synthesis by phosphorylating S6K1 and 4E-BP1 and thereby increasing ribosomal translation initiation; it phosphorylates and inactivates FOXO transcription factors, reducing atrogene expression and muscle protein degradation; and it phosphorylates GSK-3beta, promoting glycogen synthesis and cell cycle progression. Akt also drives glucose transporter translocation (GLUT4) to the cell surface in an insulin-like manner, contributing to IGF-1's glucose-lowering effect. The MAPK-ERK pathway (mitogen-activated protein kinase, extracellular signal-regulated kinase), also called the Ras-Raf-MEK-ERK cascade, is activated via Shc and Grb2-SOS recruitment to IGF-1R, driving Ras GTPase activation. This pathway promotes cell proliferation and differentiation, satellite cell activation in muscle, and is also the primary driver of the mitogenic and potential tumour-promoting effects of sustained high-amplitude IGF-1 signalling.

Why does IGF-1 LR3 have a longer effective half-life than native IGF-1?

Native IGF-1 has a plasma half-life of approximately 10 minutes as a free peptide. The majority of circulating IGF-1 is bound to IGF-binding proteins (primarily IGFBP-3), which dramatically extend its half-life but also limit its bioavailability to receptors. IGF-1 LR3 (Long R3 IGF-1) is a synthetic analogue carrying two modifications: an arginine substitution at position 3 (replacing glutamate, which is required for high-affinity IGFBP binding) and a 13-amino acid N-terminal extension peptide. These modifications reduce IGFBP binding affinity by approximately 1000-fold compared to native IGF-1. The consequence is that a far higher proportion of administered IGF-1 LR3 circulates as free, biologically active peptide, and the effective half-life increases to approximately 12 to 15 hours. IGF-1 LR3 is therefore available for receptor binding without the sequestration that limits native IGF-1 activity; however, the extended unbound fraction also prolongs the risk of hypoglycaemia and theoretically increases the duration of mitogenic IGF-1R signalling compared to brief native IGF-1 pulses.

Mechanism

IGF-1 Pathway

Insulin-like growth factor 1 (IGF-1) mediates most of growth hormone's anabolic effects in peripheral tissue. Produced primarily in the liver following GH receptor activation, IGF-1 acts on a receptor tyrosine kinase to drive PI3K-Akt-mTOR protein synthesis and MAPK-ERK cell proliferation, with IGF-1 as the primary research compound in this pathway.

Overview

IGF-1 (Insulin-like Growth Factor 1) is a 70-amino acid single-chain peptide with structural homology to proinsulin, from which it derives its name. It is the primary mediator of growth hormone's anabolic and growth-promoting effects in peripheral tissues, produced principally in the liver in response to GH receptor activation via the JAK2-STAT5b signalling cascade. The GH-IGF-1 axis is a hierarchical neuroendocrine cascade: hypothalamic GHRH (and ghrelin acting via GHS-R1a) stimulates pituitary GH secretion, circulating GH drives hepatic IGF-1 synthesis, and IGF-1 then acts on tissues throughout the body. IGF-1 also exerts negative feedback on GH secretion at both the hypothalamic level (increasing somatostatin) and the pituitary level (direct inhibition of GH secretion), forming a closed regulatory loop.

The IGF-1 receptor (IGF-1R) is structurally homologous to the insulin receptor (IR), both belonging to the receptor tyrosine kinase (RTK) family. IGF-1R is a heterotetrameric transmembrane complex consisting of two extracellular alpha subunits (which bind IGF-1) and two transmembrane beta subunits (which carry the intracellular tyrosine kinase domains). The structural and signalling homology between IGF-1R and IR means that IGF-1 at high concentrations can cross-activate the insulin receptor, contributing to the acute glucose-lowering effect observed with exogenous IGF-1 administration.

Locally produced IGF-1 in muscle, bone, and other tissues (autocrine and paracrine IGF-1) is regulated partly by local GH action and partly by mechanical loading and other stimuli, making locally produced IGF-1 a key mediator of exercise-induced muscle hypertrophy independent of circulating hepatic IGF-1.

How It Works

Understanding the IGF-1 pathway requires following the signal from IGF-1 binding at the receptor surface through to the two principal downstream cascades that drive its biological effects.

IGF-1 Receptor Activation and Autophosphorylation

IGF-1 binds to the extracellular alpha subunits of IGF-1R, inducing a conformational change that brings the intracellular beta subunit tyrosine kinase domains into proximity. This proximity triggers transphosphorylation: each kinase domain phosphorylates tyrosine residues on the opposing beta subunit, activating both kinase domains in a self-reinforcing process called autophosphorylation. Three tyrosine residues in the kinase activation loop (Y1158, Y1162, Y1163) are the primary autophosphorylation sites; their phosphorylation opens the kinase active site and enables substrate binding. Activated IGF-1R subsequently phosphorylates intracellular docking proteins including IRS-1 (insulin receptor substrate 1) and Shc, creating phosphotyrosine docking sites that recruit downstream signalling complexes.

PI3K-Akt-mTOR: The Anabolic and Survival Pathway

Phosphorylated IRS-1 recruits and activates PI3K (phosphoinositide 3-kinase, specifically the p85/p110 heterodimer). PI3K phosphorylates PIP2 (phosphatidylinositol 4,5-bisphosphate) to PIP3, which recruits PDK1 and Akt to the inner plasma membrane leaflet. PDK1 phosphorylates Akt at Thr308; mTORC2 phosphorylates Akt at Ser473, fully activating Akt. Activated Akt phosphorylates and activates mTORC1 (via TSC1/2 inhibition), which drives ribosomal protein synthesis by phosphorylating 4E-BP1 (releasing eIF4E for cap-dependent translation initiation) and S6K1 (which phosphorylates ribosomal protein S6 and eIF4B, enhancing translational capacity). Akt simultaneously phosphorylates and inactivates FOXO transcription factors, suppressing transcription of atrogin-1 and MuRF-1 (muscle ubiquitin E3 ligases responsible for muscle protein degradation), and phosphorylates GSK-3beta, inhibiting it and thereby promoting glycogen synthesis and cell cycle entry. The net anabolic effect in muscle is increased protein synthesis and decreased protein degradation, the fundamental drivers of muscle hypertrophy.

MAPK-ERK: The Proliferation and Differentiation Pathway

Phosphorylated Shc (another IGF-1R substrate) recruits the Grb2-SOS complex, which activates Ras GTPase by catalysing GDP to GTP exchange. Activated Ras (RasGTP) triggers a kinase cascade: Ras activates Raf, Raf activates MEK1/2, and MEK1/2 activate ERK1/2 (extracellular signal-regulated kinases 1 and 2) by dual phosphorylation. Activated ERK1/2 translocate to the nucleus, where they phosphorylate and activate transcription factors including Elk-1, c-Fos, and c-Jun, driving expression of immediate-early genes involved in cell cycle entry and differentiation. In muscle, MAPK-ERK signalling is important for satellite cell (muscle stem cell) proliferation and the early phase of myogenic differentiation. The MAPK-ERK pathway is also the primary mechanism by which sustained IGF-1 signalling promotes cell proliferation in a manner relevant to oncology: MAPK-ERK activates cyclin D1 expression, driving G1-S phase cell cycle progression.

IGF Binding Proteins and Free vs Bound IGF-1

At least six IGF-binding proteins (IGFBP-1 through IGFBP-6) regulate IGF-1 bioavailability by competing with IGF-1R for IGF-1 binding. IGFBP-3 is the predominant circulating IGFBP and, together with the acid-labile subunit (ALS), forms a ternary complex that carries approximately 75 to 80 percent of circulating IGF-1 with a half-life of 12 to 15 hours. IGFBP-1 and IGFBP-2 regulate acute changes in free IGF-1. Free IGF-1 (approximately 1 percent of total circulating IGF-1) is the fraction available for immediate receptor binding. IGF-1 LR3 bypasses IGFBP sequestration by virtue of its drastically reduced IGFBP affinity, increasing the free fraction from approximately 1 percent to a substantially higher proportion, and extending the effective receptor-accessible duration from minutes (native free IGF-1) to approximately 12 to 15 hours.

Peptides Investigated in This Context

Compound	Role in IGF-1 Pathway	Profile
IGF-1 (native and LR3)	Direct IGF-1R agonist; activates both PI3K-Akt-mTOR and MAPK-ERK; LR3 form bypasses IGFBP sequestration for prolonged receptor availability	View profile
BPC-157	Indirect growth factor modulator: upregulates VEGF, FGF, and PDGF expression at injury sites; does not act directly at IGF-1R	View profile

GHRPs and GHRH analogues stimulate IGF-1 indirectly by driving GH secretion, which then upregulates hepatic IGF-1 production via the GH-IGF-1 axis. The IGF-1 pathway page addresses the downstream receptor signalling; the growth hormone secretion mechanism page covers the upstream GH axis.

Research Context

IGF-1 was characterised in the late 1970s following the discovery that the liver produced a sulfation factor in response to GH. Initially termed somatomedin C, it was renamed IGF-1 after its structural homology to proinsulin was recognised. Recombinant human IGF-1 (mecasermin, Increlex) has FDA approval for growth failure in children with severe primary IGF-1 deficiency (Laron syndrome) -- conditions in which the GH-IGF-1 axis is intact at the GH secretion level but dysfunctional at the hepatic GHR or IGF-1 synthesis level. Outside of this indication, exogenous IGF-1 has no regulatory approval.

The relationship between elevated circulating IGF-1 and cancer risk is one of the most extensively studied epidemiological associations in oncology. Cohort studies have consistently associated higher serum IGF-1 levels with modestly elevated risk of colorectal, prostate, and premenopausal breast cancer. The proposed mechanism involves MAPK-ERK-driven cell proliferation and PI3K-Akt-driven suppression of apoptosis. The directionality of the association is debated; confounding by body composition, diet, and physical activity is substantial. IGF-1 is prohibited in competitive sport by WADA under the category of peptide hormones and growth factors; use is also likely prohibited in any jurisdiction that restricts unapproved biological substances for human use.

Related Mechanisms

Growth Hormone Secretion

The upstream axis: how GHRPs, GHRH analogues, and pituitary regulation drive GH and thereby IGF-1 levels.

→

Ghrelin Receptor (GHS-R1a)

GHS-R1a signalling, how GHRPs stimulate pituitary GH secretion and the downstream IGF-1 response.

→

Growth Factor Peptides, Class Overview

IGF-1 and BPC-157: direct and indirect growth factor pathway modulation.

→